preview

Medicare Psychotherapy

Decent Essays
A price tag of care for four more months of added life under Medicare coverage, may seem as an easy decision to approve based on the policies that are set. Really, on the surface we know that if you are on Medicare there is no question that you will receive the treatments that you need. Then there are those that may view this cost as it relates to government spending as an illogical expenditure for simply extending one’s life. It is with an argument such as this that particularly prompts into question the idea of what policy is in place for such funding of treatments that are covered by the Medicare program. With Medicare, as long as an individual meets the eligibility requirements of the program then they are “entitled to all of the promised…show more content…
For many countries such as Europe, care is allocated based on predetermined factors (Knickman & Kovner, 2015). For example, an individual may be meticulously examined from health history to their present state to determine whether they are approved for chemotherapy treatments. Allocating care, familiarly called rationing, allows countries to control expenses of health care (Stein, 2010). Based on numbers, the United States tops Europe by double of the amount of patients they see for dialysis treatments (Knickman & Kovner, 2015, p. 265). Withinn the United States, as long as the services are in the guidelines of policy to provide care, Medicare is going to cover those services no matter the…show more content…
Do they have concerns about the effects of the vaccine when it comes to their beneficiaries? Are they concerned because of how new the drug is on the market? What would lead Medicare to question the approval of Provenge? All the while, Medicare is not an organization that evaluates the validity of pharmaceutical drugs, that would be under the expertise of the FDA. While none of these conclusions as to why they scrutinized the company, would it be fair to state that maybe Medicare was evaluating the costs of the drug even when their policies are clear that there should not be any correlation to cost and approval to needed services? After the analysis panel that Medicare commenced during the early part of 2010, there was a suggestion of a parallel review between Medicare and the FDA for new treatments where this process “…could enhance communication among regulators, reimbursement authorities, and manufacturers while reducing the administrative burden ad providing more rapid access to new technologies” (Chambers, Pharm, & Neumann,
Get Access